Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 31, 2014, 09:57:11 AM

Login with username, password and session length


Members
  • Total Members: 23092
  • Latest: mangasa
Stats
  • Total Posts: 632493
  • Total Topics: 47901
  • Online Today: 265
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Alnylam and Biogen Idec partner on brain treatment  (Read 868 times)

0 Members and 1 Guest are viewing this topic.

Offline cmhjeff

  • Member
  • Posts: 870
Alnylam and Biogen Idec partner on brain treatment
« on: October 13, 2006, 08:55:00 AM »
Alnylam and Biogen Idec partner on brain treatment
Boston Business Journal - September 21, 2006

Drug developer Biogen Idec Inc. and Alnylam Pharmaceuticals Inc. are
collaborating to develop a treatment for progressive multifocal
leukoencephalopathy, an often deadly neurological disorder.

The condition is marked by an infection of the central nervous system
caused by the "JC virus," the companies said. The condition occurs in
immune-suppressed patients and affects the brain, often causing death
or disability.

The deal provides for Alnylam (Nasdaq: ALNY) and Biogen Idec (Nasdaq:
BIIB) to collaborate on research into PML therapies using RNAi technology.

Under the terms of the agreement, Cambridge, Mass.-headquartered
Biogen Idec will fund all research and development and Alnylam, also
in Cambridge, will receive an upfront payment of $5 million, with any
resulting products triggering additional payments to Alnylam of more
than $51 million.

"This innovative collaboration to explore using RNAi technology to
develop therapeutics for the treatment of PML will build on our work
to understand and manage this disease," said Al Sandrock, Biogen
Idec's senior vice president of neurology. "We are pleased to partner
with Alnylam, a company that has demonstrated leading capabilities in
the discovery and development of RNAi therapeutics, in this important
undertaking."

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.